aTYR PHARMA INC
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-74.1M | $-64.0M | $-50.4M | $-45.3M | $-33.8M | $-16.2M | $-16.2M | $-34.5M |
| Depreciation & Amortization | $664.0K | $708.0K | $592.0K | $232.0K | $475.0K | $569.0K | $635.0K | $746.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | — | — | — | — | — |
| Net Cash from Operating Activities | $-62.0M | $-69.1M | $-33.2M | $-41.9M | $-33.1M | $-15.3M | $-20.0M | $-31.1M |
| Investing Activities | ||||||||
| Capital Expenditures | $77.0K | $65.0K | $4.2M | $1.6M | $192.0K | $202.0K | $79.0K | $594.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-5.1M | $17.2M | $-20.1M | $47.2M | $-91.6M | $6.9M | $4.9M | $37.2M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $66.0M | $39.9M | $66.2M | $5.5M | $110.0M | $16.1M | $1.3M | $-4.2M |
| Net Change in Cash | $-1.0M | $-12.0M | $12.9M | $10.8M | $-14.6M | $7.7M | $-13.8M | $1.9M |
| Free Cash Flow | $-62.1M | $-69.2M | $-37.4M | $-43.5M | $-33.3M | $-15.5M | $-20.1M | $-31.7M |